These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2190660

  • 1. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
    Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J.
    Bone Marrow Transplant; 1990 May; 5(5):341-4. PubMed ID: 2190660
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 4. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P, Marolleau JP, Dombret H, Lepage E, Baruchel A, Adam M, Miclea JM, Sitthy X, Gisselbrecht C.
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [Abstract] [Full Text] [Related]

  • 5. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 6. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
    Armitage JO, Gingrich RD, Klassen LW, Bierman PJ, Kumar PP, Weisenburger DD, Smith DM.
    Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847
    [Abstract] [Full Text] [Related]

  • 7. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
    [Abstract] [Full Text] [Related]

  • 8. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
    Rosenfeld CS, Przepiorka D, Schwinghammer TL, Buck DS, Bloom EJ, Shadduck RK.
    Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
    [Abstract] [Full Text] [Related]

  • 9. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 10. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J.
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [Abstract] [Full Text] [Related]

  • 11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M, Al-Kgodary T.
    Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
    [Abstract] [Full Text] [Related]

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 14. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL.
    N Engl J Med; 1995 Dec 07; 333(23):1540-5. PubMed ID: 7477169
    [Abstract] [Full Text] [Related]

  • 15. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec 07; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 16. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May 07; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 17. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb 07; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 18. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
    Bone Marrow Transplant; 1998 Feb 07; 21(4):383-9. PubMed ID: 9509973
    [Abstract] [Full Text] [Related]

  • 19. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 07; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.